Podcasts about ovid therapeutics

  • 25PODCASTS
  • 31EPISODES
  • 43mAVG DURATION
  • 1MONTHLY NEW EPISODE
  • Jul 12, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about ovid therapeutics

Latest podcast episodes about ovid therapeutics

Wait, how do you spell that?: A rare disease podcast
Epilepsy and Unmet Need, feat. The LGS Foundation and Ovid Therapeutics

Wait, how do you spell that?: A rare disease podcast

Play Episode Listen Later Jul 12, 2024 42:39


This episode's guests include Dr. Tracy Dixon-Salazar, Executive Director for the Lennox-Gastaut Syndrome (LGS) Foundation, as well as Meg Alexander, Chief Strategy Officer of Ovid Therapeutics. We discuss the treatment landscape for seizure disorders such as LGS and why further research and investment is crucial. Connect with the LGS Foundation: Website - Facebook - X (Twitter) - YouTube - Instagram - LinkedIn Connect with Ovid Therapeutics:  Website - LinkedIn - X (Twitter) - Facebook Editor's Note: Chronic conditions and rare diseases don't discriminate. Patient Worthy and our partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a story to share, learn more about how your voice can help spread awareness and inspire individuals from all walks of life here: https://shorturl.at/sPV02

Biotech Clubhouse
Episode 106

Biotech Clubhouse

Play Episode Listen Later Jul 2, 2024 61:44


On this week's Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Eric Schmidt, Sam Fazeli, Bruce Booth and Grace Colon discuss the big news of the week including the FDA granting a landmark expanded approval for Sarepta's Elevidys for patients with Duchenne Muscular Dystrophy. The hosts share their varying opinions on whether the expanded approval was the right decision. The group also engages in a few discussion topics around management, including the “everything is awesome CEO” and the best and worst practices for managing a board. With multiple companies dealing with a stock drop this week (Cabaletta Bio, Kyverna Therapeutics, Taysha Gene Therapies, Aerovate Therapeutics, Ovid Therapeutics), the hosts discuss the different issues these pose for management teams and how to deal with market reactions. The group also shares thoughts on the 2024 class of IPOs, EHA 2024 highlights, BioNTech's clinical hold on its early-stage cancer drug study, and much more. This episode aired on June 21, 2024.

From Lab to Launch by Qualio
Epilepsy Breakthroughs and Beyond with Jason Tardio and Toshiya Nishi from Ovid Therapeutics

From Lab to Launch by Qualio

Play Episode Listen Later Jun 28, 2024 23:58 Transcription Available


**UPDATE** Since this episode was recorded, Takeda announced the results of the phase 3 soticlestat trials, which did not meet their primary endpoints.We welcome Dr. Toshiya Nishi and Jason Tardio from Ovid Therapeutics. Dr. Nishi, with over 20 years of experience in drug discovery, discusses his role in the development of soticlestat and ongoing research on KCC2 activators for neurological disorders. Jason Tardio, Ovid's COO, shares insights on the company's focus on rare neurological disorders, including epilepsy, and its strategic initiatives for advancing treatments. Listen to their inspiring journey from the inception of Ovid Therapeutics to its current breakthroughs, and their perspectives on fostering a quality-driven and risk-tolerant culture in drug development.https://ovidrx.com/00:00 Introduction and Welcome00:40 Meet the Guests: Dr. Toshiya Nishi and Jason Tardia02:04 The Journey of Ovid Therapeutics03:58 Discovering Saticklistat: A Serendipitous Breakthrough08:35 Strategic Initiatives and Future Directions13:48 Collaboration and Culture at Ovid Therapeutics17:38 Ensuring Quality in Drug Development21:50 Personal Insights and Closing Remarks24:07 Conclusion and FarewellQualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Xtalks Life Science Podcast
New Frontiers in Epilepsy and Seizure Treatments ft. Dr. Jeremy Levin and Meg Alexander, Ovid Therapeutics

Xtalks Life Science Podcast

Play Episode Listen Later May 15, 2024 47:51


In this episode, Ayesha spoke with Jeremy Levin, D. Phil, MB BChir, CEO and Chairman of Ovid Therapeutics Inc., and Meg Alexander, Chief Strategy Officer at Ovid.Ovid Therapeutics is a biopharmaceutical company focused on the development of medicines for epilepsies and seizure-related neurological disorders.Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries and a member of the executive committee at Bristol-Myers Squibb (BMS) Company where he was the architect, lead and implementer of the String of Pearls Strategy, which transformed BMS and facilitated the initiation and massive growth of the immuno-oncology revolution in the biopharmaceutical industry. Dr. Levin also serves on the board and executive committee of the Biotechnology Innovation Organization (BIO) as the immediate past chairman. Dr. Levin was voted as one of the 25 most influential biotechnology leaders by Fierce Biotech, one of the top three biotechnology CEOs by The Healthcare Technology Report and one of the PharmaVoice100 CEOs in 2020 and 2021. He was selected by Endpoints in 2021 as one of the 60 living pioneers of the industry, and has received several awards throughout his career. Dr. Levin has practiced medicine at university hospitals in England, South Africa and Switzerland. Meg Alexander serves as Ovid's chief strategy officer, a role in which she oversees and supports the company's corporate strategy and planning, performance measurement and risk mitigation. She also oversees the company's corporate affairs function with a focus on engaging Ovid's stakeholders across patient and caregiver communities, policymakers, press and investors.Ms. Alexander has worked in the biopharmaceutical industry for two decades and has played a key role in launching more than 25 new medicines for many conditions including rare epilepsies, ALS, HIV, multiple sclerosis, Batten's disease, cardiovascular disease and cancer. She has advised and led campaigns for large healthcare organizations, including Pfizer, Novartis, Amgen, Eli Lilly, Nestle and Coca-Cola among many others. Prior to Ovid, she founded and led the Reputation & Risk Management Group, a consultancy within Syneos Health, one of the world's largest clinical research organizations. Ms. Alexander was named a “Disruptor” and a “Rising Star” in her industry by PM360 and the Healthcare Business Women's Association, respectively.This year, OVID is expecting several CNS data readouts, including one for its lead product candidate soticlestat, which is currently in Phase III trials for the treatment of refractory seizures in Lennox-Gastaut syndrome and Dravet syndrome, a rare epilepsy with high unmet need.Tune in to the episode to learn more about Ovid Therapeutics' developmental pipeline featuring treatments for epilepsies and seizures associated with rare brain conditions.  For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/  Follow Us on Social MediaTwitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Pharma Intelligence Podcasts
Scrip Lifetime Achievement Award 2023: Jeremy Levin's Acceptance Speech

Pharma Intelligence Podcasts

Play Episode Listen Later Nov 22, 2023 9:20


In accepting Scrip's Lifetime Achievement Award, Ovid Therapeutics' CEO called on pharma to show responsible leadership and live up to its potential to do good for society.

The Readout Loud
254: The legal battle over abortion, an FDA 'bully pulpit' and Moderna's future

The Readout Loud

Play Episode Listen Later Apr 13, 2023 40:01


Jeremy Levin, CEO of Ovid Therapeutics, joins us to discuss a judge's decision to overturn the FDA approval of an abortion pill and why he believes it's the biggest threat to the biopharma industry in 50 years. We also cover the biggest news in the week of biopharma, including an update from Moderna, dispatches from a trip to FDA headquarters, and who Sen. Bernie Sanders has in his sights next.

Between the Biotech Waves
A Between the Biotech Waves Conversation with Jeremy Levin, Chair & CEO of Ovid Therapeutics

Between the Biotech Waves

Play Episode Listen Later Jan 1, 2023 71:32


Today we are talking to Jeremy Levin. Jeremy is chairman and CEO of Ovid Therapeutics, focused on rare and orphan disease of the CNS. He is the immediate past chair of BIO. Jeremy has a storied career in biotech having served as president and CEO of Teva Pharmaceutica's, a member of the exec committee of BMS where he had global responsibilities for strategy, alliances and transactions. There he devised the “String of Pearls” BD strategy which led to the acquisition of Medarex and opened the path to the successful development of the first i-onc drugs. Prior to BMS Jeremy was head of global BD and strategic alliances at Novartis. In his spare time, amazing he has any, he runs a successful Black Angus farm from which, as I understand it, many biotech CEOs get their steaks!

Biotech 2050 Podcast
128. Treating rare neurological diseases & guiding mission, Jeremy Levin, Chairman & CEO, Ovid Tx

Biotech 2050 Podcast

Play Episode Listen Later Nov 23, 2022 30:37


Synopsis: Jeremy Levin is the Chairman and CEO of Ovid Therapeutics, a company that develops medicines to treat patients with rare neurological conditions, including epilepsies and seizure-related disorders. Dr. Levin earned a PhD from Oxford and medical and surgical degrees from Cambridge before moving to the States in the late 1980s and eventually working in big pharma for companies such as Teva Pharmaceuticals and Bristol-Myers Squibb. He discusses how his formative years shaped his personal philosophy and mission to change the world for the better, the differences he experienced from running big pharma companies to early stage biotech startups, the science at Ovid and their pipeline, and his hopes for R&D in neurology over the next 10-20 years. Biography: Jeremy Levin, D.Phil, MB BChir, is chairman and chief executive officer of Ovid Therapeutics Inc. (NASDAQ: OVID), a company whose mission is to bring treatments to patients with rare neurological conditions. Dr. Levin is concurrently the chairman of Opthea (NASDAQ.OPT). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA). Before Teva, Dr. Levin was a member of the executive committee Bristol-Myers Squibb Company (NYSE: BMY). In that capacity, he was the architect, lead and implementer of the String of Pearls Strategy, which transformed Bristol and facilitated the dawn and massive growth of the immuno-oncology revolution in the biopharmaceutical industry. Dr. Levin joined Bristol from Novartis (NYSE: NVS), where he was the global head of strategic alliances. He has served as a member of the board of directors of various public and private biopharmaceutical companies, including Biocon Ltd., (NSE: BIOCON), and is currently on the board of directors of Lundbeck (OMX: LUN). Dr. Levin also serves on the board and executive committee of the Biotechnology Innovation Organization (BIO) as the immediate past chairman. Dr. Levin was voted as one of the 25 most influential biotechnology leaders by Fierce Biotech, one of the top three biotechnology CEOs by The Healthcare Technology Report and one of the PharmaVoice100 CEOs in 2020. He was selected by Endpoints in 2021 as one of the 60 living pioneers of the industry. He is the recipient of the Albert Einstein Award for Leadership in Life Sciences and the B'nai B'rith Award for Distinguished Achievement. In June 2020, he edited and published the best seller “Biotechnology in the Time of Covid-19”. Dr Levin has been widely quoted and interviewed in national and international news outlets and life science industry-related publications. He believes that the role of leaders in business is to take a public stand on public policy matters as a core part of their business strategy and responsibility to shareholders, industry and society. He is committed to a public stance on key aspects of society and industry, including, but not limited to: encouraging immigration; policies that drive innovation; patient access to medicines; the principles of diversity, equity and inclusion; the primacy of medicine and science as the sole determinants to develop medical products; and the democratic right to vote for all citizens. Dr. Levin has practiced medicine at university hospitals in England, South Africa and Switzerland. Dr. Levin earned a First-Class Bachelor in Zoology, winning the University Prize, and subsequently, was awarded a master's degree and doctorate in chromatin structure, at the University of Oxford. Thereafter, he earned his medical and surgical degrees from the University of Cambridge, where he won the Kermode Prize for his work on Captopril.

RARECast
How a Drug Setback Became a Patient Community's Gain

RARECast

Play Episode Listen Later Nov 18, 2022 35:09


In December 2020, Ovid Therapeutics' experimental therapy OV101 for the rare, neurodevelopmental condition Angelman Syndrome failed to meet its primary endpoint in a phase 3 clinical trial and the company chose to discontinue development. But rather than let the data from the study languish on the shelf, Ovid made the decision to contribute it to the Angelman Syndrome Foundation's LADDER database. We spoke to Ovid CEO Jeremy Levin and Angelman Syndrome Foundation CEO Amanda Moore, about the LADDER database, Ovid's decision to contribute its data to it, and why the two believe other drug developers should take similar steps to share their data with patients and researchers to advance the understanding of rare diseases.

ANA Investigates
ANA Investigates Genetics in Epilepsies

ANA Investigates

Play Episode Listen Later Sep 27, 2022 19:47


The role of genetics in both pediatric and adult epilepsies is expanding. Now, making a genetic diagnosis in epilepsy isn't just important for family planning and prognostication - these diagnoses can also improve patients' care starting at the moment of diagnosis. Our guest today, Ingrid Scheffer, is a leader in gene discovery in epilepsy. Dr. Scheffer is a Laureate Professor of Pediatric Neurology at the University of Melbourne, and she directs the Children's Epilepsy Research Center at Austin Health. She says while there's still a long way to go before precision medicine is available for the hundreds of known genetic epilepsies, her patients are already benefiting from genetic testing, in many ways. Dr. Scheffer was interviewed by ANA Investigates Producer and epileptologist Dr. Rohit Das of UT Southwestern Medical Center. Series 3, Episode 12. Featuring: Guest: Ingrid Scheffer, AO FRS FAA FAHMS, University of Melbourne Interviewer/Producer: Rohit Das, MD, UT Southwestern Disclosures: In the past 24 months, Ingrid Scheffer has consulted for Atheneum Partners, Biohaven Pharmaceuticals Inc, Care Beyond Diagnosis, Epilepsy Consortium and Zynerba Pharmaceuticals, has served as an investigator for Anavex Life Sciences, Cerebral Therapeutics, Cerecin Inc, Cereval Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceutical, Zogenix and Zynerba; received speaker honoraria from Biocodex, BioMarin, Chiesi, Liva Nova and UCB; received funding for travel from Biomarin, Eisai and UCB; and served on scientific advisory boards for Bellberry Ltd, BioMarin, Chiesi, Eisai, Encoded Therapeutics, Knopp Biosciences, Rogcon, Takeda Pharmaceuticals and UCB. Ingrid Scheffer may accrue future revenue on pending patent WO2009/086591: Diagnostic And Therapeutic Methods For EFMR (Epilepsy And Mental Retardation Limited To Females); has a patent for SCN1A testing held by Bionomics Inc and licensed to various diagnostic companies (WO/2006/133508); she has a patent for a molecular diagnostic/therapeutic target for benign familial infantile epilepsy (BFIE) [PRRT2] WO/2013/059884 with royalties paid.

Between the Biotech Waves
Episode 9: A Between the Biotech Waves Conversation with Yaron Werber, MD of Healthcare Biotechnology at Cowen.

Between the Biotech Waves

Play Episode Listen Later Jul 27, 2022 52:28


Today we are talking to Yaron Werber. Yaron is Managing Director of Healthcare Biotechnology at Cowen, he has over 20 years of experience as a research analyst and was a founding team member, chief business and financial officer of Ovid Therapeutics. Prior to Ovid Yaron was managing director and head of US healthcare and biotech equity research at Citi.Please note - Between vacation, other work commitments and COVID this conversation was recorded over 2 weeks ago. During that time the tea leave reading of the biotech market has marched forward with people highlighting the double bottom and climb in the XBI. While some have hailed this as the end of the bears and seeing the dust of the raging bulls in the distance I am inclined to ask what hallucinogenic they took the night before. Down rounds and negotiated valuation resets in the private market are starting to become more of a central theme with continued uncertainty about timing to recovery, 2023 is now being discussed. The landslide of public SMID cap companies that need to finance has yet to be realized while the macro economic challenges remain in place with inflation out of control in a backdrop of global destabilization. On the micro side the Seagen life raft is starting to look like a potential mirage with M&A being limited and company consolidation a whisper.In this episode Yaron and I discuss the current market metrics, what companies may want to consider and the challenges to the oft flagged oasis of consolidation, M&A and now the going private plan. We discuss his experience as an operating in a biotech company between his roles in equity research. This experience provides a unique insight into the vagaries of a biotech company and the market.

DNA Today: A Genetics Podcast
#186 n-Lorem: Nano-Rare Diseases with Luke Rosen and Wendy Chung

DNA Today: A Genetics Podcast

Play Episode Listen Later May 27, 2022


We are thrilled to share a brand new podcast that Kira Dineen co-produces, the n-Lorem “Patient Empowerment Program”. The podcast just launched so we wanted to share the pilot episode with you! This podcast focuses solely, exclusively, on the needs of nano-rare patients. These are patients that have a unique pathogenic variant (mutation) that affects only them or less than 30 people worldwide. The host of the show is Dr. Stan Crooke, who will be a familiar voice to you if you are a long time listener of DNA Today. He was on Episode 141 where we picked his brain about nano-rare patients. He is a scientist, a physician, an entrepreneur and the father of antisense technology. Dr. Crooke is responsible for more than 40 drugs in development including the famous Spinraza to treat people with spinal muscular atrophy. In this pilot episode, the host, Dr. Stan Crooke, is joined by actor and patient advocate Luke Rosen and pediatric geneticist Dr. Wendy Chung. This episode takes you on a journey to diagnosis and what it is like to live with a nano-rare disease.Luke Rosen is the board chair, KIF1A.org, vice president of patient engagement and government affairs at Ovid Therapeutics and father to Susannah. You may have seen him in Law & Order, Orange Is The New Black, Rescue Me, and Numb3rs. To learn more about KIF1A and the organization Luke and his wife, Sally, founded visit kif1a.org. You can follow Luke on Twitter @lukebrosen. Wendy Chung, M.D., Ph.D. is the Kennedy family professor of pediatrics in medicine, chief of the division of clinical genetics, department of pediatrics at Columbia University Medical Center, medical director of Columbia Genetic Counseling Graduate program and director of the clinical cancer genetics program at Columbia. Check out all the great work from Dr. Wendy Chung and her lab at Columbia by visiting wchunglab.com.The host of the show is Dr. Stanley Crooke, a scientist, a physician, an entrepreneur and the father of antisense technology. Dr. Crooke is responsible for driving the development of antisense or ASO technology, an RNA-targeted technology responsible for the commercialization of three best- and first-in class medicines and more than 40 drugs in development. In 2020, Stan formed n-Lorem to use this powerful technology to develop personalized ASO medicines for nano-rare patients (1 to 30 patients worldwide) for free, for life. On This Episode We Discuss:Susannah's journey to a diagnosisKif1A – and what a pathogenic variant (mutation) in this gene meansLiving with a nano-rare diseaseSusannah's courage and joyFinding a treatment for SusannahTo hear other episodes of the n-Lorem “Patient Empowerment Program”, subscribe on Spotify, Apple Podcast, their website, YouTube, or wherever you stream your podcasts. The host is Dr. Stan Crooke, videographer is Jon Magnuson of Mightyone Productions, producers are Jon Magnuson and Kira Dineen. Stay updated with n-Lorem on Twitter, Instagram, Facebook, Linked In, YouTube and their website, nlorem.org. Questions/inquiries can be sent to podcast@nlorem.org. Stay tuned for the next new episode of DNA Today on June 3rd! New episodes are released on Fridays. In the meantime, you can binge over 185 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel. DNA Today is hosted and produced by Kira Dineen. Our social media lead is Corinne Merlino. Our video lead is Amanda Andreoli. See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNApodcast.com. Questions/inquiries can be sent to info@DNApodcast.com. PerkinElmer Genomics is a global leader in genetic testing focusing on rare diseases, inherited disorders, newborn screening, and hereditary cancer. Testing services support the full continuum of care from preconception and prenatal to neonatal, pediatric, and adult. Testing options include sequencing for targeted genes, multiple genes, the whole exome or genome, and copy number variations. Using a simple saliva or blood sample, PerkinElmer Genomics answers complex genetic questions that can proactively inform patient care and end the diagnostic odyssey for families. Learn more at PerkinElmerGenomics.com. (SPONSORED)HemoShear Therapeutics is a clinical stage company developing new treatments for patients with rare metabolic disorders. By partnering with fellow biopharma companies, HemoShear is accelerating their drug discovery and development programs in metabolic disorders, and also liver diseases and gout. HemoShear is currently conducting a clinical trial for a new therapy for propionic and methylmalonic Acidemia. Learn more about these conditions and the clinical trial in an upcoming episode of DNA Today! You can also visit hemoshear.com. (SPONSORED)

Politics & Life Sciences (PLS) with Dean L. Fanelli, Ph.D.

My returning guest today is Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics and the immediate past Chairman of the global Biotechnology Innovation Organization. He has been voted one of the 25 most influential people in the biopharmaceutical industry. Prior to Ovid, Dr. Levin served as President and CEO of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) the world's largest generics drug company.

covid-19 ceo president phd pharma levin ovid antiviral antigens medical technology biotechnology innovation organization ovid therapeutics teva pharmaceutical industries ltd
Politics & Life Sciences (PLS) with Dean L. Fanelli, Ph.D.
Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics a

Politics & Life Sciences (PLS) with Dean L. Fanelli, Ph.D.

Play Episode Listen Later Sep 10, 2021 24:11


Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics and the immediate past Chairman of the global Biotechnology Innovation Organization (BIO), shares his latest thoughts on today's COVID-19 news: A new study in The Lancet Infectious Diseases shows Delta variant doubles the risk of hospitalization for the unvaccinated compared to the Alpha strain. New infections are up 21 percent in the last 14 days. Nationwide, COVID deaths are up 355 percent since early July. The increasing use (and benefit) of monoclonal antibody treatments. CNBC just reported on HHS data indicating that the use of mABS has increased significantly. The Lilly, Vir and Regeneron mABs are increasingly approved for use in a number of states. For those in the US, the mABs are an option for those over 65 or with pre-existing conditions who are diagnosed with Covid. An unvaccinated elementary school teacher in Marin, CA, infected half her class when she removed her mask to read aloud. "War call" in NYC streets as anti-vaxxers protest DeBlasio vaccine mandate for everyone 12 and over. Ivermectin spikes calls to Arkansas' poisons hotline after lawmakers encourage its use to treat COVID—in defiance of CDC recommendations. Ivermectin poison calls this year were four times higher than those of the past four years combined.  

Health Professional Radio - Podcast 454422
COVID Variants Make Vaccinations More Crucial

Health Professional Radio - Podcast 454422

Play Episode Listen Later Jul 27, 2021 12:16


Returning guest, Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics, Inc., and former chairman of the global Biotechnology Innovation Organization (BIO) discusses the new COVID variant Delta-Plus, a virus that mutated from the highly infective Delta version, and why vaccinations are so crucial. #OvidTherapeutics #DeltaPlus #COVID Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is a former chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA). Dr. Levin was voted as one of the twenty-five most influential biotechnology leaders by Fierce Biotech and one of the top three biotechnology CEOs in 2020 by The Healthcare Technology Report.

Jim Bohannon
Jim Bohannon 05-06-21

Jim Bohannon

Play Episode Listen Later May 7, 2021 118:05


Guests: Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics, On to discuss the Biden Administration's decision to end patent protections for COVID vaccines. Todd Bensman, Texas-based Senior National Security Fellow for the Center for Immigration Studies, On to discuss the status of the US/Mexico border. And ... Your thoughts on the voting legislation passed in Florida See omnystudio.com/listener for privacy information.

17 Minutes of Science
Episode 26: Biotechnology in the Time of COVID with Dr. Jeremy Levin

17 Minutes of Science

Play Episode Listen Later Jan 28, 2021 18:15


For episode 26 of 17 Minutes of Science, we are joined by Dr. Jeremy Levin. Dr Levin is the current chairman and CEO of Ovid Therapeutics, Inc., a company working to bring impactful treatments to patients who have rare neurological conditions. Dr. Levin is also the chairman of the Biotechnology Innovation Organization (BIO) and was named by FierceBiotech in 2018 as one fo the most influential people in biopharma. Additionally, Dr. Levin recently published a book, Biotechnology in the Time of COVID. Dr. Levin joins us on 17 Minutes of Science to discuss his recent book and to dig a bit deeper into the impact of the current coronavirus pandemic on biotech, biopharma, and clinical trials.

Honest Offense
34: Dr. Jeremy Levin on Developing Vaccines

Honest Offense

Play Episode Listen Later Jan 15, 2021 54:41


Dr. Jeremy Levin is the chairman of the Biotechnology Innovation Organization. He is also the CEO of OVID Therapeutics. Formerly, he was a member of the executive committee at Bristol-Myers Squibb and chairman and CEO of TEVA Pharmaceuticals—where he was personally recruited by the President of Israel. He is the scientist who introduced immuno-oncology to the world 10 years ago and has been called one of the most influential figures in the biopharmaceutical industry. On top of that, Dr. Levin has a fascinating life story, having been forced to flee South Africa during apartheid, and later working to develop vaccines in the heart of the Israeli–Palestinian conflict. Dr. Levin earned his B.A. in zoology, M.A. in cell biology and Ph.D. in chromatin structure, all from the University of Oxford, and his medical degree from the University of Cambridge. –––– Support the podcast and join the Honest Offense community at https://honestoffense.locals.com

Health Professional Radio - Podcast 454422
Racing for a COVID-19 Cure

Health Professional Radio - Podcast 454422

Play Episode Listen Later Nov 10, 2020 11:17


Dr. Jeremy Levin, Chairman of the global Biotechnology Innovation Organization (BIO) and Chairman and CEO of OVID Therapeutics, Inc. discusses his perspective on vaccinations and his open letter to members of the biopharmaceutical industry which outlines how public health, and the public’s trust in new medical products, are dependent upon the integrity, transparency and objective assessment of new data as it emerges. He talks about why In the summer of 2020, he gathered 47 top leaders in biopharma to co-author "Biotechnology in the Time of COVID-19: Commentaries from the Front Line" (RosettaBooks).

Jim Bohannon
Jim Bohannon 06-22-20

Jim Bohannon

Play Episode Listen Later Jun 23, 2020 118:20


Guests: Dr. Casey Mulligan, Former Member of the White House Council of Economic Advisers, On to discuss John Bolton's book. Dr. Jeremy Levin, CEO of Ovid Therapeutics, On to discuss biotechnology and COVID-19. And ... Your thoughts on the latest in the news.

Bloomberg Businessweek
The Race for a COVID-19 Vaccine

Bloomberg Businessweek

Play Episode Listen Later Jun 22, 2020 36:51


Dr. Jeremy Levin, CEO at Ovid Therapeutics, discusses the race for a COVID-19 vaccine. Bloomberg News White House Correspondent Josh Wingrove walks through the latest on politics in D.C. Bloomberg New Economy Editorial Director Andy Browne talks about his newsletter on Beijing wanting another term for President Trump. And we Drive to the Close with Jim Lowell, CIO at Adviser Investments. Hosts: Carol Massar and Jason Kelly. Producer: Doni Holloway.  Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

covid-19 ceo donald trump race drive vaccines beijing cio jason kelly ovid therapeutics jim lowell adviser investments producer doni holloway
Bloomberg Businessweek
The Race for a COVID-19 Vaccine

Bloomberg Businessweek

Play Episode Listen Later Jun 22, 2020 36:51


Dr. Jeremy Levin, CEO at Ovid Therapeutics, discusses the race for a COVID-19 vaccine. Bloomberg News White House Correspondent Josh Wingrove walks through the latest on politics in D.C. Bloomberg New Economy Editorial Director Andy Browne talks about his newsletter on Beijing wanting another term for President Trump. And we Drive to the Close with Jim Lowell, CIO at Adviser Investments. Hosts: Carol Massar and Jason Kelly. Producer: Doni Holloway. 

covid-19 ceo donald trump race drive vaccines beijing cio jason kelly ovid therapeutics jim lowell adviser investments producer doni holloway
Nature Biotechnology Podcast
Bonus: Jeremy Levin

Nature Biotechnology Podcast

Play Episode Listen Later Apr 22, 2020 46:19


A conversation with Jeremy Levin, chairman of the Biotechnology Innovation Organization and CEO of Ovid Therapeutics, about industry versus government responses to covid19, the split within biotech on how to address charges of high prices, and why the biopharma industry is so disliked. See acast.com/privacy for privacy and opt-out information.

ceo levin biotechnology innovation organization ovid therapeutics
RARECast
Why a Big Pharma Exec Embraced Rare Neurological Diseases

RARECast

Play Episode Listen Later Sep 25, 2019 38:45


Jeremy Levin’s high-profile success at building the pipeline at Bristol-Myers Squibb through deal-making and driving the company into immunotherapies, has given him the ability to take virtually any job he’d like in the biopharmaceutical sector. Given that, it may seem surprising the Big Pharma executive chose to become CEO of a development-stage company focused on rare neurological conditions. We spoke to Levin, CEO of Ovid Therapeutics, about why he took the job, the conditions the company is targeting, and whether his interest in rare diseases will shape the agenda of BIO now that he serves as chairman of the trade group.

TechNation Health Podcast
Episode 19-34 What Motivates the People Driving Biotech

TechNation Health Podcast

Play Episode Listen Later Aug 21, 2019 58:59


On this week’s Tech Nation, Moira speaks with the committed people who lead the biotech industry. Physician-entrepreneur Dr. Jeremy Levin chairs BIO, the Biotechnology Innovation Organization, and also works on the rare disease Angelman Syndrome at Ovid Therapeutics. Jim Greenwood, the CEO of BIO, asks “What’s the right thing to do?” about the price of drugs and everyday people. While BIO Vice Chair, Paul Hastings, is also the CEO of Nkarta Therapeutics. With Senior Vice President, Nadir Mahmood, they’re working with Natural Killer cells to fight cancer.

ceo driving physicians bio biotech motivates tech nation paul hastings natural killer angelman syndrome biotechnology innovation organization jim greenwood ovid therapeutics
BioTech Nation Radio Podcast
Episode 19-34 What Motivates the People Driving Biotech

BioTech Nation Radio Podcast

Play Episode Listen Later Aug 21, 2019 58:59


On this week’s Tech Nation, Moira speaks with the committed people who lead the biotech industry. Physician-entrepreneur Dr. Jeremy Levin chairs BIO, the Biotechnology Innovation Organization, and also works on the rare disease Angelman Syndrome at Ovid Therapeutics. Jim Greenwood, the CEO of BIO, asks “What’s the right thing to do?” about the price of drugs and everyday people. While BIO Vice Chair, Paul Hastings, is also the CEO of Nkarta Therapeutics. With Senior Vice President, Nadir Mahmood, they’re working with Natural Killer cells to fight cancer.

ceo driving physicians bio biotech motivates tech nation paul hastings natural killer angelman syndrome biotechnology innovation organization jim greenwood ovid therapeutics
TechNation Radio Podcast
Episode 19-34 What Motivates the People Driving Biotech

TechNation Radio Podcast

Play Episode Listen Later Aug 21, 2019 58:59


On this week’s Tech Nation, Moira speaks with the committed people who lead the biotech industry. Physician-entrepreneur Dr. Jeremy Levin chairs BIO, the Biotechnology Innovation Organization, and also works on the rare disease Angelman Syndrome at Ovid Therapeutics. Jim Greenwood, the CEO of BIO, asks “What’s the right thing to do?” about the price of drugs and everyday people. While BIO Vice Chair, Paul Hastings, is also the CEO of Nkarta Therapeutics. With Senior Vice President, Nadir Mahmood, they’re working with Natural Killer cells to fight cancer.

ceo driving physicians bio biotech motivates tech nation paul hastings natural killer angelman syndrome biotechnology innovation organization jim greenwood ovid therapeutics
Rare in Common: the podcast
Episode 11 — “I got here because I asked for help”: coming together in rare

Rare in Common: the podcast

Play Episode Listen Later Dec 20, 2018 20:46


This episode is the third in a special series recorded live at the 7th annual Global Genes RARE Patient Advocacy Summit, the largest worldwide gathering of rare disease patients, advocates, and thought leaders. When Luke Rosen’s daughter Susannah was diagnosed with a rare, neurodegenerative disease called KIF1A-associated neurological disorder (KAND) in 2016, he quickly learned there was a lack of information and resources for families like his. His desire to be there for his family and search for a treatment for KAND prompted him to leave his acting career behind and forge a new path. Two years later, as the founder of KIF1A.org and the Associate Director of Patient Engagement at Ovid Therapeutics, Luke has learned that asking for help and creating strong connections in the rare disease community are critical for navigating the challenges that arise after diagnosis.

BoldMedicine
Welcome to Ovid

BoldMedicine

Play Episode Listen Later Feb 7, 2018


In the first episode we introduce our host, Dr. Amit Rakhit, MD, MBA. Amit talks about the core philosophy that makes Ovid Therapeutics different in our approach. Amit also shares a remarkable story that inspires him to come to work every single day -- and it starts with the pictures hanging on the office walls at Ovid.  

mba md amit ovid ovid therapeutics
FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Wednesday, Jan 18, 2017

FirstWord Pharmaceutical News

Play Episode Listen Later Jan 18, 2017 1:53


Nature Biotechnology Podcast
First Rounder: Jeremy Levin

Nature Biotechnology Podcast

Play Episode Listen Later Dec 20, 2016 95:18


Jeremy Levin is chairman and CEO of Ovid Therapeutics, formerly president and CEO of Teva Pharmaceutical Industries, and former member of the executive committee at Bristol-Myers Squibb, where he led that company's 'string of pearls' strategy. His conversation with Nature Biotechnology covers shifting his mindset from treating patients to business development, his youth in South Africa, and how his past influences his view of the 2016 US presidential election results. See acast.com/privacy for privacy and opt-out information.

ceo south africa levin rounder bristol myers squibb nature biotechnology ovid therapeutics teva pharmaceutical industries